ReviewBMJ public health2026
Dengue therapeutics consortium 2025: a global collaboration in action.
Review in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is a global health emergency, with annually increasing case numbers that overwhelm healthcare systems, an ever-expanding range of the mosquito vector, and no antiviral or host-directed treatments proven to alter the course of disease. This article reports on a meeting of the Dengue Therapeutics Consortium, which included attendees from 19 countries with backgrounds in basic science, clinical research, drug development, industry, clinical trial methodology and policy. We summarise the current state of dengue therapeutics research and highlight the necessary steps to ensure that patients have equitable access to affordable and effective treatments. We review the antiviral pipeline, including novel and repurposed antiviral candidates, and we propose both human challenge and rate of viral clearance studies as methods to rapidly screen for antiviral activity prior to larger phase 3 clinical trials. We review ongoing phase 2 and phase 3 clinical trials to evaluate repurposed host-directed therapies for patients with moderate and severe disease, and we suggest considerations for future trial design, such as factorial randomisation and the use of a core outcome set to maximise efficiency and enable evidence synthesis by meta-analysis. We consider that multisectoral collaboration will be essential to achieve our aim of effective treatments for dengue. This will include drug development aligned to target product profiles, conduct of clinical trials with endpoints acceptable to both patients and regulators and sustained commitment from the pharmaceutical industry, non-profit initiatives and policymakers to ensure that effective treatments reach those who need them the most.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.